Refer to the following important safety details for information on intended use, potential side effects and risks, considerations for specific groups, and possible drug interactions linked to the prescription treatments mentioned.
Reporting Side Effects
Riovie encourages users to promptly report any side effects or adverse reactions to a licensed healthcare provider and the pharmacy that dispensed the medication. To report suspected reactions to these medications, contact the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
For emergencies, call 911 or go to your nearest emergency department.
Advertisements by Riovie
All advertisements from riovie.com are paid for by Riovie and are intended to market Riovie’s services. Some advertisements may feature paid actors or dramatizations. When real Riovie customers or endorsements are included, this will be clearly disclosed. Individual results may vary, and specific outcomes are not guaranteed.
Riovie’s Role
Riovie connects users with licensed healthcare providers for evaluations regarding the suitability of the treatments advertised. It may also assist with prescription coordination through an external pharmacy network.
Riovie acts as a managed services provider and does not offer medical advice, fill prescriptions, or function as a licensed healthcare facility or pharmacy. Instead, it provides technology and administrative support to enable medical consultations and prescription logistics. For further details, see Riovie’s Terms of Service.
Promotional Offers on riovie.com
Occasionally, the website may present promotional pricing or special introductory offers. Pricing may change at any time due to supply or market conditions at the discretion of riovie.com. Introductory or promotional pricing, including “first month” offers, applies only to the plan and product listed at the time of purchase.
Prescriptions and Medications
Prescription drugs require evaluation and approval by a qualified healthcare provider, and issuance is solely at the provider’s discretion. Access to treatment plans and medications is not assured.
Prescriptions issued through Riovie may be filled by licensed pharmacies within its affiliated network.
All prescription medications involve potential risks. Please review all associated safety details and consult your provider for personalized advice.
Compounded Drug Formulations
In certain situations, healthcare providers may prescribe compounded medications, which are custom-prepared by licensed compounding pharmacies based in the U.S. These medications are not FDA-approved for safety or effectiveness but may be used when alternatives are not available or appropriate.
Riovie helps facilitate compounded medication fulfillment via its partner pharmacy network. These formulations are personalized to meet individual patient requirements and may differ from commercial products.
Trademark Notice
Riovie is not affiliated with, sponsored by, or endorsed by the manufacturer of any brand-name medication. Any brand names referenced are the property of their respective owners and are used for identification only.
Contact Information
For any questions about Riovie’s services or advertising content, please reach out to support@riovie.com.
Tesamorelin — Subcutaneous Injection
Important Safety Information Regarding Compounded Tesamorelin
Please be aware that compounded drugs are not FDA-approved and do not undergo clinical studies to evaluate for safety and efficacy. Your healthcare provider may prescribe compounded tesamorelin based on your medical consultation.
Tesamorelin is a growth hormone-releasing hormone (GHRH) analog. It does not supply growth hormone directly; it signals the pituitary gland to release more of the body’s own. An FDA-approved tesamorelin product is indicated to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Compounded tesamorelin is prescribed at a provider’s discretion as part of a broader wellness plan, is not a weight-loss medication, and is not a substitute for diagnosing or treating growth hormone deficiency.
Do not use tesamorelin if:
- You are pregnant, trying to become pregnant, or breastfeeding.
- You have an active or suspected malignancy.
- You have had disruption of the hypothalamic-pituitary axis — pituitary surgery, a pituitary tumor, head irradiation, or head trauma.
- You have had a serious allergic reaction to tesamorelin, to mannitol, or to any component of the formulation.
Inform your healthcare provider if you:
- Have a history of cancer of any kind, or any condition being monitored for malignancy.
- Have diabetes, prediabetes, or impaired glucose tolerance — tesamorelin can raise blood sugar.
- Have untreated or poorly controlled thyroid disease, or any other endocrine disorder.
- Take corticosteroids or any medication whose blood level matters, since growth hormone can affect how some drugs are cleared.
- Are acutely or critically ill.
Serious risks include:
- Increases in IGF-1, with a theoretical potential to promote the growth of an existing malignancy
- Glucose intolerance, worsening of diabetes, or new-onset diabetes
- Serious allergic reactions, including anaphylaxis
- Fluid retention, joint pain, or carpal tunnel-type symptoms
- Injection-site infection if aseptic technique is not followed
Common side effects: injection-site reactions — redness, itching, pain, irritation, bruising or swelling — along with joint pain, muscle pain, swelling in the hands or feet, tingling or numbness, nausea, vomiting, rash, and night sweats.
Administration: Inject subcutaneously into the abdomen once daily at about the same time each day, unless your physician instructs otherwise. Use aseptic technique and rotate the injection site with every dose. Do not change your dose or frequency without speaking to your physician.
Monitoring: Your provider may order laboratory work before or during treatment, which can include IGF-1, blood glucose, and HbA1c.
Reporting side effects: Contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
